Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Prof Suresh Ramalingam presents data from the FLAURA trial during a press conference at the 2019 ESMO congress.
This was a trial looking at first-line osimertinib in patients with Ex19del/L858R EGFR mutated advanced non-small cell lung cancer (NSCLC) compared with older generation EGFR-TKIs.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php